Abstract: This disclosure provides crystalline polymorphs of squalamine phosphate, methods of making the same, and methods of treatment using the same.

Abstract: The present application relates generally to a method of treating a cutaneous or mucosal wound in a subject in need comprising topically administering to the wound site a therapeutically effective amount of a topical pharmaceutical composition comprising at least one aminosterol or a salt or derivative thereof. Also provided are methods for treating, preventing, and/or slowing the onset or progression of a disease or condition, or a symptom thereof, amenable to treatment with an aminosterol or a salt or derivative thereof in a subject in need, comprising administering to the subject a therapeutically effective amount of at least one aminosterol or a salt or derivative thereof, wherein the subject is not lying down.

Abstract: The present application relates generally to novel aminosterol compounds, compositions comprising the same, and methods of making and using the novel aminosterol compounds and compositions.

Abstract: The present application relates generally to novel aminosterol compounds, compositions comprising the same, and methods of making and using the novel aminosterol compounds and compositions.

Abstract: The present application relates generally to methods for treating, preventing and/or slowing the onset or progression of schizophrenia and/or a related symptom. The methods comprise administering at least one aminosterol or a pharmaceutically acceptable salt or derivative thereof to a subject in need.

Abstract: This invention relates to methods of treating or preventing a sleep disorder, sleep disturbance, or related symptom in a subject with aminosterols or pharmaceutically acceptable salts or derivatives thereof. In particular, the disclosed methods generally comprise administering an aminosterol to a subject in need, thereby stimulating an aminosterol-induced CNS response to treat and/or prevent a sleep disorder, sleep disturbance, or related symptom.

Abstract: Provided herein are crystalline solid forms of squalamine phosphate designated as Form 1 and Form 2, compositions containing one or both forms, and methods of their preparation and of their use.

Abstract: The present application relates generally to compositions and methods for treating and/or preventing a variety of symptoms and brain-gut disorders related thereto with aminosterols or pharmaceutically acceptable salts or derivatives thereof.

Abstract: This invention relates to novel, effective methods and compositions for mucosal, especially intranasal, delivery of a low dosage of an aminosterol for treatment and prevention of certain afflictions. Any disease or condition amenable to treatment with an aminosterol can be treated using the intranasal low dose aminosterol compositions of the invention.

Abstract: This invention relates to methods of treating and/or preventing the progression and/or onset of age-related neurodegeneration. The invention also relates to methods of reversibly slowing the growth and/or aging of a subject, and/or extending the potential lifespan of the subject, comprising administration of the naturally occurring aminosterol MSI-1436, or derivatives or salts thereof. Also described are methods of treating, preventing or delaying the onset of age-related diseases or conditions comprising administration of Aminosterol 1436, or derivatives or salts thereof.

Abstract: This invention relates to methods of treating or preventing a sleep disorder, sleep disturbance, or related symptom in a subject with aminosterols or pharmaceutically acceptable salts or derivatives thereof. In particular, the disclosed methods generally comprise administering an aminosterol to a subject in need, thereby stimulating an aminosterol-induced CNS response to treat and/or prevent a sleep disorder, sleep disturbance, or related symptom.

Abstract: Provided herein are crystalline solid forms of squalamine phosphate designated as Form 1 and Form 2, compositions containing one or both forms, and methods of their preparation and of their use.

Abstract: Described are deuterated forms of aminosterols, or a pharmaceutically acceptable salt thereof, wherein one or more hydrogen atoms at one or more positions selected from C1, C2, C3, C4, C5, C6, C7, C8, C9, C11, C12, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, and C27, are replaced with deuterium.

Abstract: The present application relates generally to methods for treating, preventing and/or slowing the onset or progression of schizophrenia and/or a related symptom. The methods comprise administering at least one aminosterol or a pharmaceutically acceptable salt or derivative thereof to a subject in need.

Abstract: The present application relates generally to compositions and methods for treating, preventing, and/or slowing the onset or progression of high blood pressure or low blood pressure and a variety of symptoms related thereto with aminosterols or pharmaceutically acceptable salts or derivatives thereof.

Abstract: Devices for cerebral and systemic cooling via a patient's nasopharyngeal cavity are described. Cooling assemblies include at least one elongate tubular member having first and second lumens, a source of liquid coolant, a gas source communicating with the first lumen, and a switch for alternately connecting the liquid coolant source to the second lumen. The first lumen transports a compressed gas and the second lumen transports a volatile liquid. The pressurized fluid may be a perfluorocarbon. The perfluorocarbon may be perfluorohexane, perfluoropentane, or 2-methyl-perfluoropentane. The gas may be air, oxygen, or a combination.

Abstract: The present application relates generally to compositions and methods for treating and/or preventing Parkinson's disease and symptoms related thereto with with compositions comprising at least one aminosterol or a pharmaceutically acceptable salt or derivative thereof.

Abstract: The present application relates generally to compositions and methods for treating, preventing, and/or slowing the onset or progression of multiple system atrophy (MSA) and a variety of symptoms related thereto with aminosterols or pharmaceutically acceptable salts or derivatives thereof.

Abstract: This invention relates to methods of treating, preventing, and/or slowing the onset or progression of cognitive impairment and/or a cognitive impairment related symptom in a subject in need. The methods, which utilize a patient-specific “fixed dose” of an aminosterol, comprise administering a therapeutically effective dose of an aminosterol to a subject in need.

Abstract: The present application relates generally to compositions and methods for treating, preventing, and/or slowing the onset or progression of erectile dysfunction (ED) and a variety of symptoms related thereto with amino sterols or pharmaceutically acceptable salts or derivatives thereof.